Prof Vladimir Tolmachev, PhD - Uppsala University - Professor

Prof Vladimir Tolmachev

PhD

Uppsala University

Professor

Uppsala | Sweden

ORCID logohttps://orcid.org/0000-0002-6122-1734

Prof Vladimir Tolmachev, PhD - Uppsala University - Professor

Prof Vladimir Tolmachev

PhD

Introduction

Primary Affiliation: Uppsala University - Uppsala , Sweden

Research Interests:

Education

Oct 1996 - Dec 1998
Uppsala University
PhD in medical science
Dec 1998
Uppsala University, Uppsala, Sweden
PhD
Feb 1984
D. Mendeleyev University of Chemical Technology, Moscow, Russia
MSc
Technology of isotopes and extra pure substances
Sep 1978 - Jan 1984
D. Mendeleyev University of Chemical Technology of Russia
MSc in chemical engineering

Experience

May 2009
Uppsala University

Publications

357Publications

2311Reads

523Profile Views

966PubMed Central Citations

Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.

Biomaterials 2019 May 14;203:73-85. Epub 2019 Feb 14.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01429612193009
Publisher Site
http://dx.doi.org/10.1016/j.biomaterials.2019.02.012DOI Listing
May 2019
16 Reads
8.557 Impact Factor

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Mol Pharm 2019 Mar 8;16(3):995-1008. Epub 2019 Feb 8.

Nuclear Medicine Department, Cancer Research Institute , Tomsk National Research Medical Center Russian Academy of Sciences , Tomsk , Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00922DOI Listing
March 2019
11 Reads
4.384 Impact Factor

Basic and practical concepts of radiopharmaceutical purification methods.

Drug Discov Today 2019 01 29;24(1):315-324. Epub 2018 Sep 29.

Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2018.09.018DOI Listing
January 2019
26 Reads
6.691 Impact Factor

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.

Eur J Pharm Biopharm 2019 Jan 5;134:37-48. Epub 2018 Nov 5.

Department of Protein Technology, KTH - Royal Institute of Technology, SE-10691 Stockholm, Sweden.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09396411183105
Publisher Site
http://dx.doi.org/10.1016/j.ejpb.2018.11.004DOI Listing
January 2019
38 Reads
3.383 Impact Factor

Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.

Oncol Rep 2019 Jan 15;41(1):534-542. Epub 2018 Oct 15.

Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, SE-106 91 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/or.2018.6792
Publisher Site
http://dx.doi.org/10.3892/or.2018.6792DOI Listing
January 2019
11 Reads
2.191 Impact Factor

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.

J Control Release 2018 Oct 30;288:84-95. Epub 2018 Aug 30.

Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2018.08.040DOI Listing
October 2018
18 Reads
7.705 Impact Factor

Preclinical Evaluation of [Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.

Cells 2018 Sep 18;7(9). Epub 2018 Sep 18.

Department of Immunology, Genetics and Pathology, Uppsala University, SE- 751 85 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells7090141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162391PMC
September 2018
16 Reads

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Theranostics 2018 7;8(16):4462-4476. Epub 2018 Aug 7.

Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.24395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134937PMC
August 2018
14 Reads
7.830 Impact Factor

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.

Mol Pharm 2018 08 25;15(8):3394-3403. Epub 2018 Jul 25.

Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health , KTH Royal Institute of Technology , Stockholm , Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00393DOI Listing
August 2018
10 Reads
1 Citation
4.384 Impact Factor

Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga.

Mol Pharm 2018 07 20;15(7):2674-2683. Epub 2018 Jun 20.

Department of Immunology, Genetics and Pathology , Uppsala University , 751 85 Uppsala , Sweden.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acs.molpharmaceut.8b00204
Publisher Site
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00204DOI Listing
July 2018
34 Reads
4.384 Impact Factor

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology.

J Nucl Med 2018 06 15;59(6):885-891. Epub 2018 Mar 15.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.117.199901DOI Listing
June 2018
30 Reads
3 Citations
6.160 Impact Factor

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Contrast Media Mol Imaging 2018 6;2018:6930425. Epub 2018 Jun 6.

Molecular Immunology Laboratory, Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6930425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011117PMC
June 2018
35 Reads
2.923 Impact Factor

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.

Sci Rep 2018 Jun 25;8(1):9643. Epub 2018 Jun 25.

Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-27886-0
Publisher Site
http://dx.doi.org/10.1038/s41598-018-27886-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018533PMC
June 2018
36 Reads
5.080 Impact Factor

Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe.

Sci Rep 2018 Feb 14;8(1):2998. Epub 2018 Feb 14.

Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-21283-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812989PMC
February 2018
19 Reads
5.080 Impact Factor

Evaluation of the first Sc-labeled Affibody molecule for imaging of HER2-expressing tumors.

Nucl Med Biol 2017 02 18;45:15-21. Epub 2016 Oct 18.

Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2016.10.004DOI Listing
February 2017
33 Reads
2 Citations
2.412 Impact Factor

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Theranostics 2016 1;6(2):262-71. Epub 2016 Jan 1.

3. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.13502DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729774PMC
January 2017
13 Reads
29 Citations
7.830 Impact Factor

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.

Int J Oncol 2016 Dec 5;49(6):2285-2293. Epub 2016 Oct 5.

Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118000PMC
December 2016
12 Reads
6 Citations
3.025 Impact Factor

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.

Mol Pharm 2016 11 27;13(11):3676-3687. Epub 2016 Sep 27.

Department of Immunology, Genetics and Pathology, Uppsala University , SE-75285 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.6b00502DOI Listing
November 2016
17 Reads
6 Citations
4.384 Impact Factor

Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.

Bioconjug Chem 2016 Nov 27;27(11):2678-2688. Epub 2016 Oct 27.

Department of Protein Technology, KTH - Royal Institute of Technology , SE-10691 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.6b00465DOI Listing
November 2016
13 Reads
2 Citations
4.513 Impact Factor

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.

Theranostics 2016 1;6(1):93-103. Epub 2016 Jan 1.

2. School of Biotechnology, Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.12766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679357PMC
October 2016
19 Reads
11 Citations
7.830 Impact Factor

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

Int J Oncol 2016 Sep 6;49(3):1185-94. Epub 2016 Jul 6.

School of Biotechnology, Division of Protein Technology, KTH - Royal Institute of Technology, SE-10691 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3614DOI Listing
September 2016
23 Reads
4 Citations
3.025 Impact Factor

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.

J Nucl Med 2016 06 9;57(6):867-71. Epub 2016 Feb 9.

Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.169342DOI Listing
June 2016
17 Reads
13 Citations
6.160 Impact Factor

Novel chemoselective (18)F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions.

Chem Commun (Camb) 2016 May 4;52(36):6083-6. Epub 2016 Apr 4.

Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Vladimir-Prelog Weg 4, CH-8093 Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c6cc01982jDOI Listing
May 2016
9 Reads
4 Citations
6.834 Impact Factor

Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.

Mol Pharm 2016 05 6;13(5):1668-78. Epub 2016 Apr 6.

Institute for Immunology, Genetics and Pathology, Uppsala University , 751 05 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.6b00089DOI Listing
May 2016
18 Reads
6 Citations
4.384 Impact Factor

Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.

Int J Oncol 2016 May 9;48(5):2124-34. Epub 2016 Mar 9.

Division of Molecular Imaging, Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3429DOI Listing
May 2016
18 Reads
2 Citations
3.025 Impact Factor

PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.

Int J Oncol 2016 Apr 2;48(4):1325-32. Epub 2016 Feb 2.

Institute of Immunology, Genetic and Pathology, Uppsala University, SE-75185 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777594PMC
April 2016
28 Reads
9 Citations
3.025 Impact Factor

Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.

J Nucl Med 2016 Mar 10;57(3):431-6. Epub 2015 Dec 10.

Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.162248DOI Listing
March 2016
7 Reads
8 Citations
6.160 Impact Factor

Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins.

Bioconjug Chem 2016 Mar 29;27(3):716-26. Epub 2016 Jan 29.

Department of Protein Technology, KTH - Royal Institute of Technology , SE-10691, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.5b00677DOI Listing
March 2016
9 Reads
2 Citations
4.513 Impact Factor

Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells in vitro.

Biomater Sci 2016 Feb;4(2):250-4

Science for Life Laboratory, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c5bm00355eDOI Listing
February 2016
6 Reads
1 Citation

Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.

Int J Oncol 2016 Feb 14;48(2):461-70. Epub 2015 Dec 14.

Department of Immunology, Genetics and Pathology Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725455PMC
February 2016
14 Reads
3 Citations
3.025 Impact Factor

ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.

Cancer Res 2015 Oct 21;75(20):4364-71. Epub 2015 Aug 21.

Department of Protein Technology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3497DOI Listing
October 2015
45 Reads
4 Citations
9.330 Impact Factor

Affibody-mediated PET imaging of HER3 expression in malignant tumours.

Sci Rep 2015 Oct 19;5:15226. Epub 2015 Oct 19.

Division of Protein Technology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep15226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609989PMC
October 2015
5 Reads
16 Citations
5.080 Impact Factor

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.

Int J Oncol 2015 Aug 4;47(2):601-9. Epub 2015 Jun 4.

School of Biotechnology, Division of Protein Technology, KTH - Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2015.3027DOI Listing
August 2015
43 Reads
3 Citations
3.025 Impact Factor

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

Oncol Rep 2015 Aug 9;34(2):1042-8. Epub 2015 Jun 9.

Preclinical PET Platform, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2015.4046DOI Listing
August 2015
10 Reads
9 Citations
2.191 Impact Factor

Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes.

PLoS One 2014 22;9(9):e107483. Epub 2014 Sep 22.

Department of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0107483PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171488PMC
June 2015
12 Reads
3 Citations
3.234 Impact Factor

The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.

Nucl Med Biol 2015 May 20;42(5):446-454. Epub 2014 Dec 20.

Preclinical PET Platform, Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2014.12.009DOI Listing
May 2015
48 Reads
4 Citations
2.412 Impact Factor

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity.

ChemistryOpen 2015 Apr 12;4(2):174-82. Epub 2015 Jan 12.

Biomedical Radiation Sciences, Faculty of Medicine, Uppsala University 751 85, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/open.201402097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420590PMC
April 2015
11 Reads
2 Citations
2.940 Impact Factor

Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.

Amino Acids 2015 Feb 27;47(2):303-15. Epub 2014 Nov 27.

Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00726-014-1859-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302241PMC
February 2015
11 Reads
6 Citations
3.293 Impact Factor

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.

Int J Oncol 2015 Feb 27;46(2):513-20. Epub 2014 Nov 27.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2014.2782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277246PMC
February 2015
35 Reads
7 Citations
3.025 Impact Factor

Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

Curr Pharm Des 2014 ;20(14):2275-92

Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S-751 81 Uppsala, Sweden.

View Article

Download full-text PDF

Source
January 2015
16 Reads
1 Citation
3.452 Impact Factor

Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.

Mol Pharm 2014 Nov 23;11(11):3957-64. Epub 2014 Jul 23.

Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University , Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/mp500284t
Publisher Site
http://dx.doi.org/10.1021/mp500284tDOI Listing
November 2014
27 Reads
8 Citations
4.384 Impact Factor

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.

Eur J Med Chem 2014 Nov 26;87:519-28. Epub 2014 Sep 26.

KTH Royal Institute of Technology, School of Biotechnology, Division of Protein Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2014.09.082DOI Listing
November 2014
70 Reads
4 Citations
3.450 Impact Factor

Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.

Eur J Nucl Med Mol Imaging 2014 Jul 13;41(7):1450-9. Epub 2014 Mar 13.

Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-014-2733-7DOI Listing
July 2014
9 Reads
10 Citations
5.383 Impact Factor

First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.

J Nucl Med 2014 May 24;55(5):730-5. Epub 2014 Mar 24.

Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.113.131243DOI Listing
May 2014
11 Reads
46 Citations
6.160 Impact Factor

Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain.

J Alzheimers Dis 2013 ;37(1):29-40

Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-130029DOI Listing
April 2014
24 Reads
12 Citations
4.151 Impact Factor

Methods for radiolabelling of monoclonal antibodies.

Methods Mol Biol 2014 ;1060:309-30

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-586-6_16DOI Listing
March 2014
8 Reads
2 Citations

Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.

J Nucl Med 2014 Feb 9;55(2):294-300. Epub 2014 Jan 9.

Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.113.121814DOI Listing
February 2014
15 Reads
9 Citations
6.160 Impact Factor

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Cancer Immunol Res 2014 Jan 21;2(1):80-90. Epub 2013 Oct 21.

Authors' Affiliations: Department of Immunotechnology, Lund University, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0067DOI Listing
January 2014
20 Reads
16 Citations

Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.

Bioconjug Chem 2014 Jan 27;25(1):82-92. Epub 2013 Dec 27.

Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology , Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc400343rDOI Listing
January 2014
7 Reads
4 Citations
4.513 Impact Factor

Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.

Bioconjug Chem 2013 Jun 5;24(6):1102-9. Epub 2013 Jun 5.

Division of Biomedical Radiation Sciences, Department of Medicinal Chemistry, Uppsala University, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc300678yDOI Listing
June 2013
64 Reads
9 Citations
4.513 Impact Factor

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

J Nucl Med 2013 Jun 25;54(6):961-8. Epub 2013 Mar 25.

Preclinical PET Platform, Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.112.110700DOI Listing
June 2013
8 Reads
9 Citations
6.160 Impact Factor

HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.

J Med Chem 2013 Jun 14;56(12):4966-74. Epub 2013 Jun 14.

Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm400218yDOI Listing
June 2013
20 Reads
10 Citations
5.450 Impact Factor

Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.

Nucl Med Biol 2013 Apr 26;40(3):378-86. Epub 2013 Jan 26.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S-751 81 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2012.12.009DOI Listing
April 2013
7 Reads
3 Citations
2.412 Impact Factor

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.

Eur J Nucl Med Mol Imaging 2013 Feb 21;40(3):439-49. Epub 2012 Nov 21.

Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-012-2284-8DOI Listing
February 2013
39 Reads
8 Citations
5.383 Impact Factor

Engineering of affibody molecules for therapy and diagnostics.

Methods Mol Biol 2012 ;899:103-26

Affibody AB, Solna, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-61779-921-1_7DOI Listing
December 2012
8 Reads
27 Citations

Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design.

Drug Discov Today 2012 Nov 8;17(21-22):1224-32. Epub 2012 Jul 8.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2012.07.002DOI Listing
November 2012
6 Reads
8 Citations
6.691 Impact Factor

The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36.

Mol Med Rep 2010 Jan-Feb;3(1):155-60

Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Uppsala University Hospital (Akademiska Sjukhuset), Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr_00000233DOI Listing
October 2012
8 Reads
1.484 Impact Factor

Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.

Bioconjug Chem 2012 Aug 17;23(8):1661-70. Epub 2012 Jul 17.

Division of Molecular Biotechnology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc3002369DOI Listing
August 2012
54 Reads
7 Citations
4.513 Impact Factor

Multi-channel Si-liquid crystal filter with fine tuning capability of individual channels for compensation of fabrication tolerances.

Nanoscale Res Lett 2012 Jul 12;7(1):387. Epub 2012 Jul 12.

Department of Electronic and Electrical Engineering, Trinity College Dublin, College Green, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1556-276X-7-387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458977PMC
July 2012
34 Reads
1 Citation
2.780 Impact Factor

Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.

J Nucl Med 2012 Jun 14;53(6):953-60. Epub 2012 May 14.

Department of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.111.101527DOI Listing
June 2012
36 Reads
18 Citations
6.160 Impact Factor

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.

Tumour Biol 2012 Jun 17;33(3):641-51. Epub 2012 Jan 17.

Division of Molecular Biotechnology, School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-011-0305-zDOI Listing
June 2012
7 Reads
8 Citations
2.840 Impact Factor

Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.

Amino Acids 2012 May 15;42(5):1975-85. Epub 2011 May 15.

Division of Biomedical Radiation Sciences, Department of Radiology, Oncology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, 75185, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00726-011-0927-xDOI Listing
May 2012
33 Reads
3 Citations
3.293 Impact Factor

Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.

Nucl Med Biol 2012 May 14;39(4):518-29. Epub 2011 Dec 14.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2011.10.013DOI Listing
May 2012
30 Reads
1 Citation
2.412 Impact Factor

Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line.

Int J Oncol 2012 May 19;40(5):1677-82. Epub 2011 Dec 19.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovského 1203, 50005 Hradec Králové, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2011.1307DOI Listing
May 2012
9 Reads
10 Citations
3.025 Impact Factor

Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.

Eur J Nucl Med Mol Imaging 2012 Apr 15;39(4):693-702. Epub 2011 Dec 15.

Division of Molecular Biotechnology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-011-2016-5DOI Listing
April 2012
4 Reads
2 Citations
5.383 Impact Factor

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Eur J Nucl Med Mol Imaging 2012 Mar 30;39(3):481-92. Epub 2011 Nov 30.

Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-011-1992-9DOI Listing
March 2012
57 Reads
9 Citations
5.383 Impact Factor

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.

J Nucl Med 2012 Jan 15;53(1):146-53. Epub 2011 Dec 15.

Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.111.093047DOI Listing
January 2012
53 Reads
13 Citations
6.160 Impact Factor

Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.

J Nucl Med 2012 Jan 15;53(1):90-7. Epub 2011 Dec 15.

Division of Biomedical Radiation Sciences, Department of Radiology, Oncology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.111.090829DOI Listing
January 2012
69 Reads
16 Citations
6.160 Impact Factor

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.

Nucl Med Biol 2011 Nov 22;38(8):1093-102. Epub 2011 Jun 22.

Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2011.04.005DOI Listing
November 2011
5 Reads
3 Citations
2.412 Impact Factor

Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.

Cancer Biother Radiopharm 2011 Oct 11;26(5):593-601. Epub 2011 Aug 11.

Unit of Otolaryngology and Head and Neck Surgery, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2011.0981DOI Listing
October 2011
10 Reads
1 Citation
1.381 Impact Factor

125I-labeled quercetin as a novel DNA-targeted radiotracer.

Cancer Biother Radiopharm 2011 Aug 28;26(4):469-75. Epub 2011 Jul 28.

Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, 17 Kilometers Khazar abad Boulevard, Sari, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2010.0951DOI Listing
August 2011
3 Reads
1.381 Impact Factor

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

Nucl Med Biol 2011 Jul 3;38(5):697-706. Epub 2011 Mar 3.

Division of Biomedical Radiation Sciences, Department of Radiology, Oncology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2010.11.013DOI Listing
July 2011
28 Reads
1 Citation
2.412 Impact Factor

Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I.

J Med Chem 2011 Jun 12;54(11):3817-26. Epub 2011 May 12.

Department of Molecular Biotechnology, Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm200065eDOI Listing
June 2011
14 Reads
8 Citations
5.450 Impact Factor

Silicon photonic crystal filter with ultrawide passband characteristics.

Opt Lett 2011 May;36(10):1854-6

Department of Electronic and Electrical Engineering, Trinity College Dublin, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1364/OL.36.001854DOI Listing
May 2011
7 Reads
3.292 Impact Factor

Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.

Bioconjug Chem 2011 May 12;22(5):894-902. Epub 2011 Apr 12.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc100470xDOI Listing
May 2011
11 Reads
7 Citations
4.513 Impact Factor

Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.

Int J Oncol 2011 Apr 20;38(4):1137-43. Epub 2011 Jan 20.

Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S-751 85 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2011.915DOI Listing
April 2011
21 Reads
6 Citations
3.025 Impact Factor

Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfalls.

Curr Radiopharm 2011 Apr;4(2):76-89

Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden.

View Article

Download full-text PDF

Source
April 2011
28 Reads
2 Citations

Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab.

Hum Antibodies 2010 ;19(4):107-11

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/HAB-2010-0234DOI Listing
March 2011
2 Reads

Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.

J Nucl Med 2011 Mar 14;52(3):461-9. Epub 2011 Feb 14.

School of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.110.083592DOI Listing
March 2011
5 Reads
14 Citations
6.160 Impact Factor

Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Eur J Nucl Med Mol Imaging 2011 Mar 11;38(3):531-9. Epub 2010 Nov 11.

Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-010-1646-3DOI Listing
March 2011
6 Reads
9 Citations
5.383 Impact Factor

Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.

Protein Expr Purif 2011 Mar 26;76(1):127-35. Epub 2010 Oct 26.

Division of Molecular Biotechnology, School of Biotechnology, AlbaNova University Center, Royal Institute of Technology (KTH), SE-106 91 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pep.2010.10.008DOI Listing
March 2011
5 Reads
3 Citations
1.700 Impact Factor

Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

J Biol Chem 2011 Feb 7;286(7):5234-41. Epub 2010 Dec 7.

Centre for Immune Regulation, Department of Molecular Biosciences, University of Oslo, 0316 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M110.164848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3037636PMC
February 2011
12 Reads
36 Citations
4.573 Impact Factor

Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.

Lancet Oncol 2010 Oct 26;11(10):992-1000. Epub 2010 Jul 26.

Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70088-7DOI Listing
October 2010
11 Reads
20 Citations
24.690 Impact Factor

Radionuclide molecular imaging using Affibody molecules.

Curr Pharm Biotechnol 2010 Sep;11(6):581-9

Division of Nuclear Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
September 2010
25 Reads
11 Citations
2.511 Impact Factor

Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine.

Nucl Med Biol 2010 Jul 8;37(5):539-46. Epub 2010 Apr 8.

Division of Nuclear Medicine, Department of Medical Sciences, Uppsala University, SE-751 85, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2010.02.009DOI Listing
July 2010
10 Reads
5 Citations
2.412 Impact Factor

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

Eur J Nucl Med Mol Imaging 2010 Jul 4;37(7):1356-67. Epub 2010 Feb 4.

Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 751 81, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-009-1367-7DOI Listing
July 2010
16 Reads
21 Citations
5.380 Impact Factor

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

J Nucl Med 2010 Jun 19;51(6):892-7. Epub 2010 May 19.

Zentralklinik Bad Berka GmBH, PET-Zentrum, Bad Berka, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.073239DOI Listing
June 2010
4 Reads
67 Citations
6.160 Impact Factor

Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods.

Biochim Biophys Acta 2010 May 11;1800(5):487-510. Epub 2010 Feb 11.

Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, SE-75181 Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbagen.2010.02.002DOI Listing
May 2010
7 Reads
15 Citations

Design of an optimized scaffold for affibody molecules.

J Mol Biol 2010 Apr 10;398(2):232-47. Epub 2010 Mar 10.

Affibody AB, Lindhagensgatan 133, SE-112 51 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2010.03.002DOI Listing
April 2010
9 Reads
26 Citations
4.333 Impact Factor

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.

Eur J Nucl Med Mol Imaging 2010 Mar 17;37(3):613-22. Epub 2009 Oct 17.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 751 81, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-009-1283-xDOI Listing
March 2010
11 Reads
28 Citations
5.380 Impact Factor

(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Eur J Nucl Med Mol Imaging 2010 Feb 22;37(2):260-9. Epub 2009 Sep 22.

Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-009-1268-9DOI Listing
February 2010
4 Reads
6 Citations
5.380 Impact Factor

Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging.

Eur J Nucl Med Mol Imaging 2009 Nov 6;36(11):1864-73. Epub 2009 Jun 6.

Department of Radiology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-009-1176-zDOI Listing
November 2009
16 Reads
9 Citations
5.380 Impact Factor

The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.

Eur J Nucl Med Mol Imaging 2009 Sep 9;36(9):1460-8. Epub 2009 May 9.

Affibody AB, Bromma, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-009-1134-9DOI Listing
September 2009
17 Reads
4 Citations
5.380 Impact Factor

Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.

Bioorg Med Chem Lett 2009 Jul 25;19(14):3912-4. Epub 2009 Mar 25.

School of Biotechnology, Royal Institute of Technology, AlbaNova University Centre, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.03.083DOI Listing
July 2009
16 Reads
1 Citation
2.420 Impact Factor

Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.

Biopolymers 2009 ;92(2):116-23

School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bip.21142DOI Listing
June 2009
5 Reads
2 Citations
2.380 Impact Factor

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.

Eur J Nucl Med Mol Imaging 2009 Apr 10;36(4):692-701. Epub 2008 Dec 10.

Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-008-1003-yDOI Listing
April 2009
18 Reads
7 Citations
5.380 Impact Factor

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.

J Nucl Med 2009 Feb 21;50(2):274-83. Epub 2009 Jan 21.

Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Department of Medical Sciences, Nuclear Medicine, Uppsala University, and Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.108.055525DOI Listing
February 2009
7 Reads
31 Citations
6.160 Impact Factor

Top co-authors

Anna Orlova
Anna Orlova

Preclinical PET Platform

77
Mohamed Altai
Mohamed Altai

Uppsala University

29
Bogdan Mitran
Bogdan Mitran

Uppsala University

24
Hadis Honarvar
Hadis Honarvar

Uppsala University

24
Zohreh Varasteh
Zohreh Varasteh

Preclinical PET Platform

15
Joanna Strand
Joanna Strand

Rudbeck Laboratory

14